Last reviewed · How we verify
NRL-1
NRL-1 is a neuroactive steroid that enhances GABAergic inhibitory neurotransmission in the central nervous system.
NRL-1 is a neuroactive steroid that enhances GABAergic inhibitory neurotransmission in the central nervous system. Used for Acute repetitive seizures (clusters), Status epilepticus.
At a glance
| Generic name | NRL-1 |
|---|---|
| Also known as | Intranasal diazepam |
| Sponsor | Neurelis, Inc. |
| Drug class | Neuroactive steroid; GABA-A receptor positive allosteric modulator |
| Target | GABA-A receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
NRL-1 acts as a positive allosteric modulator of GABA-A receptors, increasing the frequency and duration of chloride channel opening to enhance inhibitory signaling. This mechanism is intended to provide rapid seizure control and potentially address other conditions involving excessive neuronal excitability.
Approved indications
- Acute repetitive seizures (clusters)
- Status epilepticus
Common side effects
- Somnolence
- Dizziness
- Headache
- Fatigue
Key clinical trials
- Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects (PHASE3)
- Repeat-Dose Pharmacokinetics Study of NRL-1 in Epilepsy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |